Inhibition of Mnk-eIF4E pathway sensitizes the efficacy to chemotherapy in anaplastic thyroid cancer

被引:13
|
作者
Hu, Kun [1 ]
Zhang, Juan [2 ]
Yu, Min [3 ]
Xiong, Chang'e [4 ]
机构
[1] Yangtze Univ, Jingzhou Cent Hosp, Thyroid Surg Dept, Clin Med Coll 2, Jingzhou, Peoples R China
[2] Yangtze Univ, Jingzhou Cent Hosp, Dept Endocrinol, Clin Med Coll 2, Jingzhou, Peoples R China
[3] Yangtze Univ, Jingzhou Cent Hosp, Galactophore Dept, Clin Med Coll 2, Jingzhou, Peoples R China
[4] Hubei Univ Sci & Technol, Sch Basic Med Sci, Xianning, Peoples R China
关键词
chemotherapy; eIF4E; Mnk; thyroid cancer; CELL-GROWTH; TRANSLATION; APOPTOSIS; PHOSPHORYLATION; PROGRESSION; CARCINOMA; THERAPY; EIF4E; LINES; MNKS;
D O I
10.2217/fon-2016-0320
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: We investigated whether MAPK-interacting kinase (Mnk) inhibition sensitizes anaplastic thyroid cancer (ATC) cellular response to chemotherapy. Materials & methods: In vitro and in vivo methods were used to examine the combinatory effects of cisplatin with Mnk inhibition and its underlying mechanism. Results: Mnk inhibition by pharmacological or genetic approaches inhibits proliferation and induces apoptosis of ATC cells and enhances the effects of cisplatin in in vitro and in vivo. Mechanistically, cisplatin increases eIF4E phosphorylation in a dose-and time-dependent manner in ATC cells. Mnk inhibitors sensitize the efficacy of cisplatin by inhibiting cisplatin-induced eIF4E phosphorylation. Conclusion: Targeting Mnk-eIF4E pathway provides a therapeutic strategy by sensitizing ATC response to chemotherapeutic drug.
引用
收藏
页码:489 / 498
页数:10
相关论文
共 50 条
  • [21] Inhibition of mTORC1 Enhances the Translation of Chikungunya Proteins via the Activation of the MnK/eIF4E Pathway
    Joubert, Pierre-Emmanuel
    Stapleford, Kenneth
    Guivel-Benhassine, Florence
    Vignuzzi, Marco
    Schwartz, Olivier
    Albert, Matthew L.
    PLOS PATHOGENS, 2015, 11 (08)
  • [22] MNK/eIF4E inhibition overcomes anlotinib resistance in non-small cell lung cancer
    Zhang, Qi
    Li, Hui
    Li, Quan
    Hu, Qiyan
    Liu, Bo
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 (02) : 245 - 252
  • [23] Interleukin-6 induces nascent protein synthesis in human dorsal root ganglion nociceptors primarily via MNK-eIF4E signaling
    Mitchell, Molly E.
    Torrijos, Gema
    Cook, Lauren F.
    Mwirigi, Juliet M.
    He, Lucy
    Shiers, Stephanie
    Price, Theodore J.
    NEUROBIOLOGY OF PAIN, 2024, 16
  • [24] Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in mice
    Kwegyir-Afful, Andrew K.
    Murigi, Francis N.
    Purushottamachar, Puranik
    Ramamurthy, Vidya P.
    Martin, Marlena S.
    Njar, Vincent C. O.
    ONCOTARGET, 2017, 8 (32) : 52381 - 52402
  • [25] The MNK-1/eIF4E pathway as a new therapeutic pathway to target inflammation and remodelling in asthma
    Seidel, Petra
    Sun, Qingzhu
    Costa, Luigi
    Lardinois, Didier
    Tamm, Michael
    Roth, Michael
    CELLULAR SIGNALLING, 2016, 28 (10) : 1555 - 1562
  • [26] BRAF V600E Inhibition in Anaplastic Thyroid Cancer
    Rosove, Michael H.
    Peddi, Parvin F.
    Glaspy, John A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (07): : 684 - 685
  • [27] EGPI-1, a novel eIF4E/eIF4G interaction inhibitor, inhibits lung cancer cell growth and angiogenesis through Ras/MNK/ERK/eIF4E signaling pathway
    Qi, Xueju
    Zhang, Shuna
    Chen, Zekun
    Wang, Lijun
    Zhu, Wenyong
    Yin, Chuanjin
    Fan, Junting
    Wu, Xiaochen
    Wang, Jing
    Guo, Chuanlong
    CHEMICO-BIOLOGICAL INTERACTIONS, 2022, 352
  • [28] Metformin blocks MYC protein synthesis in colorectal cancer via mTOR-4EBP-eIF4E and MNK1-eIF4G-eIF4E signaling
    Shen, Peng
    Reineke, Lucas C.
    Knutsen, Erik
    Chen, Meng
    Pichler, Martin
    Ling, Hui
    Calin, George A.
    MOLECULAR ONCOLOGY, 2018, 12 (11) : 1856 - 1870
  • [29] Inhibiting eIF4E phosphorylation sensitizes triple-negative breast cancer to CDK4/6 inhibition
    Deng, Qiyun
    Amiri, Mehdi
    Piric, Anastasija Ana
    Bagherian, Yasaman
    Li, Zilan
    Huang, Sidong
    Pollak, Michael
    Sonenberg, Nahum
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (06)
  • [30] Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer
    Gibson, William J.
    Ruan, Daniel T.
    Paulson, Vera A.
    Barletta, Justine A.
    Hanna, Glenn J.
    Kraft, Stefan
    Calles, Antonio
    Nehs, Matthew A.
    Moore, Francis D., Jr.
    Taylor-Weiner, Amaro
    Wala, Jeremiah A.
    Zack, Travis I.
    Lee, Thomas C.
    Fennessy, Fiona M.
    Alexander, Erik K.
    Thomas, Tom
    Janne, Pasi A.
    Garraway, Levi A.
    Carter, Scott L.
    Beroukhim, Rameen
    Lorch, Jochen H.
    Van Allen, Eliezer M.
    CLINICAL CANCER RESEARCH, 2017, 23 (09) : 2367 - 2373